MASH Combination Therapy: 2026 Pipeline & M&A Update
MASH drug development is shifting from monotherapy to combinations. M&A by Madrigal, GSK, Sagimet, key combination regimens, and preclinical model tips.
1. The Paradigm Shift in MASH: From Monotherapy to Combinations
The landscape of MASH (Metabolic dysfunction-associated steatohepatitis) drug discovery fundamentally changed in 2024 with the FDA approval of Resmetirom (Rezdiffra), the world's first MASH therapy. However, as detailed in the MAESTRO-NASH trial outcomes, resmetirom as a monotherapy achieved fibrosis improvement in approximately 25% of patients. It is now widely accepted that there is no single "magic bullet" to cure all patients.
MASH is a highly complex, multi-factorial disease driven by overlapping cascades of metabolic dysfunction (insulin resistance, lipotoxicity), chronic inflammation, and progressive fibrogenesis. Therefore, much like the management of oncology or hypertension, combination therapies targeting different mechanisms of action are universally recognized as the future Standard of Care (SoC).
Between 2025 and 2026, the industry has witnessed a frenzy of M&A activity and licensing deals as mega-pharma and biotech companies race to construct proprietary "combination platforms."
2. Key Player Acquisitions: Who Acquired What?
Companies are aggressively assembling different therapeutic "puzzle pieces"—such as systemic metabolic modifiers (like GLP-1s), direct anti-fibrotics, and lipid synthesis inhibitors—to develop "best-in-class" Fixed-Dose Combinations (FDCs).
2.1 Madrigal Pharmaceuticals: Expanding the Champion's Portfolio
As the pioneer of the MASH market, Madrigal is proactively acquiring external assets to amplify the efficacy of its approved THR-β agonist, resmetirom.
- Acquiring a GLP-1: Madrigal secured an exclusive global license from CSPC Pharmaceutical Group for a preclinical oral GLP-1 receptor agonist (SYH2086, an orforglipron derivative) for an upfront payment of $120 million (with potential milestones reaching $2 billion)1. The strategy is clear: combine the profound weight-loss and systemic metabolic benefits of an oral GLP-1 with the direct hepatic lipid and fibrosis reduction of resmetirom into a single, once-daily oral pill.
- Acquiring a DGAT2 Inhibitor: Furthermore, Madrigal acquired the exclusive global rights to Pfizer's Phase 2 DGAT2 inhibitor (ervogastat) for $50 million2. While Pfizer previously developed ervogastat in combination with an ACC inhibitor (clesacostat), Madrigal correctly identified that pairing this lipid synthesis inhibitor with resmetirom could yield powerful synergistic effects on liver fat clearance.
2.2 Sagimet Biosciences: Targeting F4 Cirrhotic MASH
Sagimet Biosciences, developing the next-generation Fatty Acid Synthase (FASN) inhibitor, denifanstat, is also heavily pivoting towards combination therapies.
- Combination with Resmetirom: Sagimet is targeting "F4 MASH" (compensated cirrhosis), a severe patient population currently lacking any approved therapies. They recently completed a Phase 1 pharmacokinetic (PK) trial combining denifanstat and resmetirom, confirming safety and good tolerability3. Mechanistically, the pairing is highly complementary: FASN inhibition shuts off hepatic De Novo Lipogenesis (DNL) — the "inflow tap" — while the THR-β agonist resmetirom accelerates β-oxidation of pre-existing lipid — the "outflow burner". This "close the tap, open the burner" synergy is expected to achieve hepatic lipid rebalancing and anti-fibrotic effects unattainable by either monotherapy alone.
- Preparing for FDCs: To enhance patient convenience, Sagimet signed an exclusive global license agreement with TAPI (a Teva subsidiary) to utilize innovative forms of resmetirom's active pharmaceutical ingredient (API)4. Armed with this, Sagimet plans to launch a Phase 2 Proof-of-Concept (PoC) combination trial in the second half of 2026.
2.3 GSK (GlaxoSmithKline): Blending FGF21 with siRNA
Mega-pharma GSK, long seeking a dominant foothold in hepatology, made a massive financial move to acquire a validated MASH asset.
- Acquiring an FGF21 Analogue: GSK acquired efimosfermin, a Phase 3-ready FGF21 analogue, from Boston Pharmaceuticals for $1.2 billion upfront (and up to $800M in milestones)5. FGF21 has repeatedly demonstrated powerful metabolic correction and rapid fibrosis regression.
- Synergy with In-House siRNA: GSK's broader strategic goal is to evaluate efimosfermin both as a monotherapy and in combination with its proprietary siRNA therapeutic (GSK'990), which is currently in development for MASH and ALD. This blend of a peptide therapeutic with gene silencing represents a highly novel, dual-pronged attack on the disease.
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
3. Active Combination Regimen Landscape
A consolidated snapshot of the leading MASH combination regimens as of April 2026. Development phase and target population reveal which combinations are positioned for which MASH disease stages.
| Combination Regimen | Developer | Mechanism Pairing | Phase | Target Population |
|---|---|---|---|---|
| Resmetirom + SYH2086 | Madrigal | THR-β + oral GLP-1RA | Preclinical→Ph1 | Obese + F2-F3 MASH |
| Resmetirom + ervogastat | Madrigal | THR-β + DGAT2 inhibitor | Ph2 prep | F2-F3 MASH |
| Resmetirom + denifanstat | Sagimet | THR-β + FASN inhibitor | Ph2 PoC (2H 2026 start) | F4 compensated cirrhotic MASH |
| efimosfermin ± GSK'990 | GSK | FGF21 + siRNA | Ph3 (monotherapy first) | F2-F4 MASH/ALD |
| Semaglutide + Efruxifermin | Novo Nordisk (post-Akero acquisition) | GLP-1RA + FGF21 | Preclinical → Ph2 planned | Obese + F2-F3 MASH |
| Tirzepatide + antifibrotic | Eli Lilly (internal pipeline) | GLP-1/GIP + TBD | Under consideration | Obese + advanced MASH |
A structural signal: Novo Nordisk and Eli Lilly are assembling both the metabolic backbone and antifibrotic assets in-house, creating a competitive constraint where other players must prove synergy on top of a Novo/Lilly backbone rather than own the baseline themselves.
4. Designing Combination Models: Preclinical Practical Considerations
MASH pathology is not so simple that combining two effective drugs automatically yields double the efficacy. When designing preclinical in vivo combination trials at CROs, several critical factors must be meticulously addressed.
① Selecting the Right Animal Model
The chosen model must properly manifest both the "metabolic" and "fibrotic" aspects of the disease. A simple chemical-induced Carbon Tetrachloride (CCl4) model is inappropriate because it cannot evaluate the metabolic benefits of drugs like GLP-1s. For combination studies, long-term dietary models like the GAN (Gubra-Amylin NASH) diet are preferred. The study must comprehensively assess body weight, insulin resistance, and hepatic histological scores (NAS and fibrosis).
② Establishing "Standard of Care (SoC)" Benchmarks
In the 2026 era, a simple "Untreated (Vehicle) Control" arm is no longer sufficient for regulatory or partnering purposes. Preclinical study designs must include a "Resmetirom Monotherapy" arm and/or a "Semaglutide (GLP-1) Monotherapy" arm. To prove a compound's worth, researchers must demonstrate that their novel combination delivers a statistically significant "add-on effect" or absolute "synergy" over these existing SoC benchmarks across endpoints such as NAS, Sirius red/PSR area fraction, hydroxyproline content, and Pro-C3.
③ Drug-Drug Interaction (DDI) and PK Profiling
The liver is the primary organ for drug metabolism. MASH-afflicted liver models naturally have impaired metabolic capacity. When dosing two compounds simultaneously, it is crucial to perform early PK profiling to ensure that cytochromes are not catastrophically competing, which could lead to toxic spikes in compound blood concentrations or negated efficacy. Resmetirom in particular is an OATP1B1/1B3 substrate, so interaction screening with combination partners is essential.
5. Conclusion: The Burden of Proving "Synergy"
Post-2026 MASH drug discovery has firmly transitioned from the era of "finding novel mechanisms" to the era of the "portfolio puzzle"—determining how to most elegantly combine treatments.
No survey of this reshaping is complete without Novo Nordisk and Eli Lilly, the undisputed giants of the incretin space. Novo Nordisk captured the first-ever GLP-1RA MASH indication with Wegovy (semaglutide) in August 2025, then closed its up-to-$5.2B acquisition of Akero Therapeutics (developer of the FGF21 analog Efruxifermin) in December 2025, assembling a "metabolic backbone × anti-fibrotic" one-stop platform in-house (see EFX deep-dive). Eli Lilly, armed with Tirzepatide (GLP-1/GIP) — already posting strong fibrosis improvements in SYNERGY-NASH Ph2 — plus oral orforglipron and the tri-agonist retatrutide, is positioning to rewrite the MASH Standard-of-Care itself. In other words, while Madrigal, GSK, and Sagimet are buying individual puzzle pieces, Novo and Lilly are moving upstream to own the baseline therapy itself — leaving every other player structurally constrained to demonstrate synergy on top of a Novo or Lilly backbone.
The aggressive acquisitions and strategic pivots by top players like Madrigal, GSK, and Sagimet cement this reality. The vital question for any biotech now is: Which existing therapy does my pipeline pair with best? By leveraging advanced MASH animal models and rigorous digital pathology early in preclinical development to provide undeniable evidence of "synergy," drug developers can secure their position in the rapidly evolving MASH market.
References & Press Releases
1. Madrigal Pharmaceuticals. "Madrigal Pharmaceuticals Enters into Exclusive Global Licensing Agreement with CSPC for Oral GLP-1 Receptor Agonist SYH2086." GlobeNewsWire. July 30, 2025. (Press Release)
2. Madrigal Pharmaceuticals. "Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement with Pfizer for Ervogastat, a Clinical-Stage Oral DGAT-2 Inhibitor." GlobeNewsWire. January 9, 2026. (Press Release)
3. Sagimet Biosciences. "Sagimet Biosciences Announces Positive Phase 1 PK Results for Denifanstat and Resmetirom Combination." GlobeNewsWire. December 18, 2025. (Press Release)
4. Sagimet Biosciences. "Sagimet Biosciences Enters Global, Exclusive License Agreement with TAPI for Resmetirom API." GlobeNewsWire. December 17, 2025. (Press Release)
5. GSK plc. "GSK to acquire efimosfermin alfa from Boston Pharmaceuticals to strengthen steatotic liver disease pipeline." gsk.com. May 2025. (Press Release)
Related Articles
- Efruxifermin (EFX): HARMONY/SYMMETRY + Novo Acquisition — Market-reshaping $5.2B Novo deal (Dec 2025); core THR-β+FGF21 combo candidate
- Survodutide (BI 456906): GLP-1/GCG Dual Agonist for MASH — LIVERAGE Ph3 ongoing; prime Resmetirom combination candidate
- MASH Drug Development: Comprehensive Analysis — Cross-sectional evidence review
- Liver Antifibrotic Drug Frontier 2026 — FGF21 and incretin class development trends
- MASH Model Selection Guide — Models optimal for combination evaluation